1 – 29 of 29
- show: 250
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Molecular patterns of resistance to immune checkpoint blockade in melanoma
(
- Contribution to journal › Article
- 2022
-
Mark
Transcriptomic signatures of tumors undergoing T cell attack
(
- Contribution to journal › Article
-
Mark
DNA promoter hypermethylation of melanocyte lineage genes determines melanoma phenotype
(
- Contribution to journal › Article
-
Mark
B Cells and Tertiary Lymphoid Structures : Friends or Foes in Cancer Immunotherapy?
(
- Contribution to journal › Scientific review
- 2021
-
Mark
Clinical efficacy of T-cell therapy after short-term BRAF-inhibitor priming in patients with checkpoint inhibitor-resistant metastatic melanoma
(
- Contribution to journal › Article
-
Mark
Tumour gene expression signature in primary melanoma predicts long-term outcomes
(
- Contribution to journal › Article
-
Mark
BRN2 is a non-canonical melanoma tumor-suppressor
(
- Contribution to journal › Article
-
Mark
Rapid Identification of the Tumor-Specific Reactive TIL Repertoire via Combined Detection of CD137, TNF, and IFNγ, Following Recognition of Autologous Tumor-Antigens
(
- Contribution to journal › Article
- 2020
-
Mark
Tumor genetic heterogeneity analysis of chronic sun-damaged melanoma
(
- Contribution to journal › Article
-
Mark
Tertiary lymphoid structures improve immunotherapy and survival in melanoma
(
- Contribution to journal › Article
-
Mark
Analysis of DNA methylation patterns in the tumor immune microenvironment of metastatic melanoma
(
- Contribution to journal › Article
-
Mark
The Role of PTEN Loss in Immune Escape, Melanoma Prognosis and Therapy Response
(
- Contribution to journal › Article
-
Mark
Qualitative analysis of tumor-infiltrating lymphocytes across human tumor types reveals a higher proportion of bystander CD8+ T cells in non-melanoma cancers compared to melanoma
(
- Contribution to journal › Article
-
Mark
Escape from nonsense-mediated decay associates with anti-tumor immunogenicity
(
- Contribution to journal › Article
- 2019
-
Mark
Performance of gene expression-based single sample predictors for assessment of clinicopathological subgroups and molecular subtypes in cancers : a case comparison study in non-small cell lung cancer
(
- Contribution to journal › Article
-
Mark
Transcriptomic analysis reveals prognostic molecular signatures of stage I melanoma
(
- Contribution to journal › Article
-
Mark
The X-Linked DDX3X RNA Helicase Dictates Translation Reprogramming and Metastasis in Melanoma
(
- Contribution to journal › Article
- 2017
-
Mark
NF1-mutated melanoma tumors harbor distinct clinical and biological characteristics
(
- Contribution to journal › Article
-
Mark
Acquired immune resistance follows complete tumor regression without loss of target antigens or IFNγ signaling
(
- Contribution to journal › Article
-
Mark
Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma
(
- Contribution to journal › Article
-
Mark
Rare variant, gene-based association study of hereditary melanoma using whole-exome sequencing
(
- Contribution to journal › Article
- 2016
-
Mark
Consensus of Melanoma Gene Expression Subtypes Converges on Biological Entities
(
- Contribution to journal › Letter
-
Mark
Multiregion whole-exome sequencing uncovers the genetic evolution and mutational heterogeneity of early-stage metastatic melanoma
(
- Contribution to journal › Article
-
Mark
High TERT promoter mutation frequency in non-acral cutaneous metastatic melanoma
(
- Contribution to journal › Letter
- 2015
-
Mark
Molecular stratification of metastatic melanoma using gene expression profiling: prediction of survival outcome and benefit from molecular targeted therapy.
(
- Contribution to journal › Article
-
Mark
Genome-Wide DNA Methylation Analysis in Melanoma Reveals the Importance of CpG Methylation in MITF Regulation.
(
- Contribution to journal › Article
- 2014
-
Mark
Primary Melanoma Tumors from CDKN2A Mutation Carriers do not Belong to a Distinct Molecular Subclass.
(
- Contribution to journal › Article
-
Mark
Molecular and genetic diversity in the metastatic process of melanoma.
(
- Contribution to journal › Article
- 2012
-
Mark
Molecular profiling reveals low- and high-grade forms of primary melanoma
(
- Contribution to journal › Article